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hepatitis B: Two double-blind, randomized, placebo-controlled
studies.
Background. The incidence of adefovir dipivoxil (ADV)
nephrotoxicity has been previously reported with the 60 and
120 mg daily dose in human immunodeficiency virus (HIV).
We report a complete analysis on the renal tolerance of ADV
at the currently approved dose of 10 mg daily for the treatment
of chronic hepatitis B.
Methods. To investigate the efficacy, safety, and the tolera-
bility of two dosing regimens of ADV (10 mg daily or 30 mg
daily), two double-blind, placebo-controlled studies were per-
formed in patients with chronic hepatitis B and compensated
liver disease who were not undergoing current treatment and
who had evidence of hepatitis B virus (HBV) replication.
Results. There was no overall median change from baseline at
week 48 in serum creatinine or serum phosphorus levels in the
ADV 10 mg group. In the ADV 30 mg group there was a slight
increase of 0.2 mg/dL in median serum creatinine levels, and
decrease of 0.1 mg/dL in serum phosphorus levels at week 48.
Serum creatinine increase and hypophosphatemia were more
frequently observed in patients receiving ADV 30 mg daily com-
pared with ADV 10 mg and placebo. There were no grade 4
proteinuria, hematuria, or glycosuria events.
Conclusion. Mild nephrotoxicity was demonstrated with the
dose of 30 mg daily. Nephrotoxicity, as defined by an increase
≥0.5 mg/dL from baseline in serum creatinine or a serum phos-
phorus value of <1.5 mg/dL on two consecutive occasions, was
not observed in patients treated with ADV 10 mg for a median
follow-up period of approximately 64 weeks.
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Adefovir dipivoxil (ADV) is an orally bioavailable
prodrug of adefovir, a phosphonate nucleotide ana-
logue of adenosine monophosphate that possesses po-
tent in vitro activity against hepadnaviruses [wild-type
and lamivudine-resistant hepatitis B virus (HBV)], retro-
viruses, and herpes viruses. The active intracellular moi-
ety, adefovir diphosphate, acts as a competitive inhibitor
and chain-terminator of HBV replication mediated by
HBV DNA polymerase. ADV is eliminated by the kid-
neys via glomerular filtration and active tubular secre-
tion. In previous clinical studies in HIV, nephrotoxicity
was confirmed as the most important limiting toxicity of
ADV therapy, with doses six to 12 times higher than the
recommended 10 mg daily dose for chronic hepatitis B
therapy. Nephrotoxicity at the 60 and 120 mg daily dose
was characterized by mild to moderate changes in renal
tubular function. Their onset was similar at all doses and
duration of treatment, but their incidence and severity
was dose related.
The safety and efficacy of a once-daily dose of ADV
10 mg were previously assessed in an open-label trial for
the treatment of lamivudine-resistant HBV infection in
HIV-1–infected patients [1]. However, renal abnormali-
ties are frequently observed in HIV-1–infected patients,
and controlled studies are necessary to clearly assess the
renal tolerance of ADV at the current approved dose of
10 mg daily.
We report a complete analysis on the renal safety of
ADV 10 mg and 30 mg daily for the treatment of patients
with chronic hepatitis B from two double-blind, random-
ized, placebo-controlled studies [2, 3].
METHODS
To investigate the efficacy, the renal safety, and the tol-
erability of two dosing regimens of ADV (10 mg daily
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or 30 mg daily) in patients with chronic hepatitis B, two
double-blind, placebo-controlled studies, GS-98–437 and
GS-98–438 (hereafter referred to as studies 437 and 438)
were performed in patients with chronic hepatitis B and
compensated liver disease who were not undergoing cur-
rent treatment and who had evidence of HBV replication.
Principal entry criteria included active viral replication
(≥5 log10 copies/mL) and elevated alanine aminotrans-
ferase (ALT) levels (≥1.2 times the upper limit of nor-
mal). The use of a placebo control group in studies 437
and 438 was considered critical for the purpose of sepa-
rating the effects of ADV from the effects of the patients’
possible chronic hepatitis B–related disease progression.
The integrated safety population from these studies in-
cludes 492 patients who were treated at the recommended
regimen of ADV 10 mg once daily with a median dura-
tion of exposure of 48 weeks (maximum 92 weeks). For
the identification of adverse events and laboratory abnor-
malities, a comparison of ADV 10 mg with placebo and of
ADV 30 mg with ADV 10 mg during the first double-blind
48 weeks of treatment is presented. Concomitant use
of nephrotoxic drugs (aminoglycosides, amphotericin B,
vancomycin, cidofovir, foscarnet, cisplatin, pentamidine)
or competitors of renal excretion (probenecid, sulfin-
pyrazone) was not allowed. Hepatotoxic drugs (anabolic
steroids, ketaconazole; itraconazole, isoniazid, rifampin,
rifabutin) were similarly excluded.
Study 437
Study GS-98–937 is a phase III study designed to evalu-
ate the safety and efficacy of ADV 10 and 30 mg compared
with placebo in patients with HbeAg-positive hepatitis
B. A total of 515 patients were randomized in this study:
170 assigned to the placebo group, 172 to the ADV 10 mg
group, and 173 to the ADV 30 mg group. Four patients did
not receive study drug, so the intent-to-treat (ITT) popu-
lation comprised 511 patients (placebo 167 patients, ADV
10 mg 171 patients, ADV 30 mg 173 patients). Among the
511 patients who received at least one dose of study drug,
472 (92%) of the patients completed 48 weeks of dosing
with their assigned treatment. The completion rate was
similar among the three treatment groups. Four hundred
and fifty-nine patients were rerandomized to the second
48-week treatment period, of which two patients were not
treated, and 22 patients received an incorrect treatment
assignment at their first visit of the second 48-week pe-
riod. Therefore, a total of 435 patients entered the second
48-week treatment period and received at least one cor-
rect treatment assignment (138 placebo patients to ADV
10 mg, 85 ADV 10 mg patients to continue active treat-
ment, 70 ADV 10 mg patients to receive placebo, and
142 ADV 30 mg patients to receive placebo). Twelve pa-
tients (3%) discontinued drug during the second 48-week
period while receiving correct treatment. Nine of these
patients were in the ADV 30 mg to placebo group, and
none were in the group that continued on ADV 10 mg.
Study 438
Study GS-98–438 is a phase III study designed to pro-
vide additional evaluations of the efficacy and safety of
ADV dipivoxil 10 mg once daily in patients with HbeAg-
negative, presumed precore mutant, chronic hepatitis B.
Placebo was used as a control because the only licensed
therapies have not demonstrated adequate efficacy in this
population. The reassignment of dose group at the be-
ginning of the second 48 weeks allows all patients in the
study to receive at least 48 weeks of active treatment,
provides evaluation of different durations of treatment,
and assesses the effect of treatment withdrawal. A total
of 185 patients were randomized into study 438: 62 as-
signed to the placebo group and 123 assigned to the ADV
10 mg group. One patient randomized to the placebo
group never received study drug so the ITT population
comprised 184 patients. Four patients discontinued study
before completing 48 weeks of treatment: in the ADV
group, one patient was lost to follow-up, two patients
withdrew consent, and one patient became HIV-positive.
All 180 patients who completed treatment in study 438
were randomized to receive treatment for the second
48-week treatment period; 60 placebo patients to ADV
10 mg, 80 ADV dipivoxil patients to continue active treat-
ment, and 40 ADV patients to receive placebo. Only one
ADV 10 mg patient did not receive a dose of study med-
ication during year two.
Main outcome measures
Changes in serum creatinine and serum phosphorus
have been identified as the most sensitive and specific lab-
oratory abnormalities associated with adefovir-related
nephrotoxicity, and consequently these two chemistries
have been carefully monitored. For the evaluation of lab-
oratory data, the overall incidence of abnormalities has
been summarized by toxicity grade based on the Gilead
Sciences-modified National Insitute of Allergy and Infec-
tious Diseases toxicity grading scale [4].
Statistical analysis
All analyses were intent-to-treat. Changes over time
in laboratory values were analyzed both using a linear
model and a repeated measures model, adjusting for
baseline value. P values were calculated based on a pro-
portional hazard regression model. Kaplan-Meier esti-
mates were compared using a log-rank P value. Fisher
exact test was used to compare proportions.
RESULTS
The efficacy results of these studies and some safety
analysis were recently reported [2, 3].
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Table 1. Study 437: Demographic and baseline disease characteristics
Placebo ADV 10 mg ADV 30 mg
Characteristic (N = 167) (N = 171) (N = 173)
Demographics
Age years
Mean ± SD 37 ± 11.8 34 ± 11.2 34 ± 10.8
Median 35 32 32
Q1 to Q3 28 to 43 25 to 42 26 to 41
Male sex, No. % 119 (71) 130 (76) 129 (75)
Race or ethnic group, No. %
White 60 (36) 60 (35) 64 (37)
Black 3 (2) 8 (5) 5 (3)
Asian 101 (60) 102 (60) 101 (58)
Other 3 (2) 1 (1) 3 (2)
Baseline Knodell Score
Median total score 10.0 9.5 10.0
Median fibrosis score 1.0 1.0 1.0
Median necro-inflammatory 8.0 7.0 8.0
score
ALT IU/L
Median 94 95 92
≤ULN 3 (2) 3 (2) 4 (2)
>ULN 164 (98) 168 (98) 169 (98)
Median multiple of ULN 2.4 2.3 2.3
HBV DNA log10 copies/mL
Median log HBV DNA 8.33 8.40 8.34
Table 2. Study 438: Demographic and baseline disease characteristics
Placebo ADV 10 mg All
Characteristic (N = 61) (N = 123) (N = 184)
Demographics
Age years
Mean ± SD 45 ± 10.4 46 ± 9.8 46 ± 10.0
Median 45 46 46
Q1 to Q3 39 to 53 40 to 53 39 to 53
Male sex, No. % 50 (82) 102 (83) 152 (83)
Race or ethnic group, No. %
Caucasian 40 (66) 82 (67) 122 (66)
Black 1 (2) 5 (4) 6 (3)
Asian 20 (33) 36 (29) 56 (30)
Baseline Knodell Score
Median total score 9.0 10.0 10.0
Median fibrosis score 1.0 1.0 1.0
Median necro-inflammatory 7.0 8.0 7.0
score
ALT IU/L
Median 100 93 98
≤ULN 2 (3) 7 (6) 9 (5)
>ULN 59 (97) 116 (94) 175 (95)
Median multiple of ULN 2.4 2.3 2.3
HBV DNA log10 copies/mL
Median log HBV DNA 7.05 7.10 7.08
The demographic and baseline characteristics of the
populations in the clinical efficacy studies are summarized
in Table 1 (study 437) and Table 2 (study 438).
Serum creatinine and serum phosphorus
Study 437. At 48 weeks, there was no median change
from baseline in serum creatinine, while median serum
phosphorus levels increased by 0.1 mg/dL in the ADV
10 mg group (Table 3).
Table 3. Study 437: Serum phosphorus and creatinine abnormalities
Placebo ADV 10 mg ADV 30 mg
Grade N (%) N (%) N (%)
Hypophosphatemia mg/dL 161 170 173
1 (2.0–2.2) 8 (5) 6 (4) 15 (9)
2 (1.5–<2.0) 9 (5) 4 (2) 21 (12)
3 (1.0–1.5) 0 (0) 1 (<1) 5 (3)
4 (<1.0) 0 (0) 0 (0) 1 (<1)
Creatinine mg/dL 147 170 171
1 (1.5–2.0) 0 (0) 2 (1) 17 (10)
2 (>2.0–3.0) 0 (0) 0 (0) 0 (0)
3 (>3.0–6.0) 0 (0) 0 (0) 0 (0)
4 (>6.0)- 0 (0) 0 (0) 0 (0)
In the ADV 30 mg group, there was a slight increase of
0.2 mg/dL in median serum creatinine levels and decrease
of 0.1 mg/dL in serum phosphorus levels at week 48.
Among the adverse events considered by the investiga-
tors to be related to study medication, hypophosphatemia
was reported in 6% of the ADV 30 mg group compared
with 1% in the ADV 10 mg and placebo groups.
Increased serum creatinine was reported in 10%, 1%,
and <1% of the ADV 30 mg, ADV 10 mg, and placebo
groups, respectively. There was no serum creatinine in-
crease in the adefovir 10 mg treated patients compared
with 8% in the adefovir 30 mg group.
Two patients had a grade 1 serum creatinine eleva-
tion in the ADV 10 mg group; however, neither of these
events were ≥0.5 mg/dL above baseline, as confirmed by
two consecutive laboratory assessments. Thirty-three pa-
tients (21% Kaplan-Meier estimate) in the ADV 30 mg
group experienced a ≥0.5 mg/dL increase from baseline
in serum creatinine by week 48. Grades 3 and 4 serum
creatinine elevations were reported in six of 110 ADV
30 mg patients (4%) (Table 2). These patients had pre-
existing renal dysfunction at baseline (one patient with
grade 1 at baseline, and three patients with grade 3 at
baseline). Thirty-one (89%) of the serum creatinine ab-
normalities in the ADV 30 mg group resolved.
Most patients had normal serum phosphorus levels
during treatment. Of those patients who had grade 2 hy-
pophosphatemia, similar incidences were reported in the
placebo (5%) and ADV 10 mg (2%) groups. One patient
in the ADV 10 mg group and six patients in the ADV
30 mg group experienced transient serum phosphorus
levels of <1.5 mg/dL at some time while on study drug.
All resolved to ≥2.2 mg/dL. There were no serum phos-
phorus values of <1.5 mg/dL as determined by two con-
secutive laboratory assessments in either ADV 30 mg
and 10 mg. One case of Fanconi syndrome was reported
as being possibly related to study drug in a patient
treated with ADV 30 mg daily for approximately six
months. In this case, laboratory abnormalities included
hypophosphatemia (grade 3) and slight elevation of
serum creatinine, although serum creatinine remained
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Table 4. Study 438: Serum phosphorus and creatinine abnormalities
Placebo ADV 10 mg
Grade N (%) N (%)
Hypophosphatemia mg/dL
1 (2.0–2.2) 1 (2) 6 (5)
2 (1.5–< 2.0) 1 (2) 4 (3)
3 (1.0–1.5) 0 (0) 0 (0)
4 (<1.0) 0 (0) 0 (0)
Creatinine mg/dL
1 (1.5–2.0) 0 (0) 1 (<1)
2 (>2.0–3.0) 0 (0) 0 (0)
3 (>3.0–6.0) 0 (0) 0 (0)
4 (>6.0)- 0 (0) 0 (0)
within normal limits. Hypophosphatemia continued with
discontinuation of study drug and oral phosphorus sup-
plementation.
In the ADV 30 mg group, 42 patients (24%) had their
dose reduced by week 48 due to an adverse event or
abnormal laboratory result, including protocol-defined
dose reductions based on serum creatinine and/or serum
phosphorus abnormalities. In the ADV 10 mg group,
five patients (3%) had such dose reductions, as did two
patients (1%) in the placebo group. Following a proto-
col amendment, such dose reductions for mild changes in
serum creatinine (0.3 to 0.4 mg/dL) were amended, and
replaced by permanent study drug dose discontinuation
for serum creatinine increase ≥0.5 mg/dL, as confirmed
by two consecutive laboratory assessments. This strat-
egy was implemented to allow better characterization of
ADV dose-dependent renal tolerance and practical uti-
lization. Finally, there was a greater occurrence of grade
1 and grade 2 hematuria in the ADV 30 mg group than
in the ADV 10 mg or placebo groups.
Study 438. We observed no marked serum phosphorus
or serum creatinine changes, defined as a shift from no
abnormality at baseline to ≥grade 3 during study or from
grade 1 at baseline to grade 4 during study, in either of
the ADV treatment or the placebo groups (Table 4).
Urinalysis (only assessed in study 437).
Hematuria. There was a greater occurrence of grade
1 and 2 hematuria in the ADV 30 mg group (12% and
17%, respectively) compared with the ADV 10 mg (6%
and 11%) or the placebo group (7% and 10%). There was
no difference in the occurrence of hematuria between the
placebo and the ADV 10 mg groups. All three groups had
a similar rate of grade 3 hematuria events. There were no
grade 4 hematuria events (Table 5).
Proteinuria. There was a greater occurrence of grade
1 and 2 proteinuria in the ADV 30 mg group (22% and
13%, respectively) compared with the ADV 10 mg (14%
and 6%) or the placebo groups (10% and 7%). There was
no difference in the occurrence of proteinuria between
the placebo and the ADV 10 mg groups. There were no
grade 3 or 4 proteinuria events (Table 5).
Table 5. Study 437: Urinary parameters in HBV-infected patients
Adefovir Adefovir
Placebo 10 mg 30 mg
Grades No. (%) No. (%) (%)
Hematuria N = 166 N = 170 N = 171
1 <10 RBCs 11 (7) 11 (6) 21 (12)
2 10–100 RBCs 17 (10) 18 (11) 29 (17)
3 >100 RBCs 21 (13) 21 (12) 23 (13)
4 Obstructive or Rx required 0 (0) 0 (0) 0 (0)
Glycosuria N = 167 N = 170 N = 171
1 (+1) 5 (3) 1 (<1) 3 (2)
2 (+2) 3 (2) 1 (<1) 3 (2)
3 (+3) 5 (3) 1 (<1) 2 (1)
4 (+4) 0 (0) 0 (0) 0 (0)
Proteinuria mg/dL N = 167 N = 170 N = 171
1 (<100) 17 (10) 24 (14) 38 (22)
2 (100–1000) 11 (7) 10 (6) 23 (13)
3 (>1000) 0 (0) 0 (0) 0 (0)
4 (Nephrotic syndrome) 0 (0) 0 (0) 0 (0)
Glycosuria. There were no differences in the inci-
dence of grade 1 to 3 events between treatment groups.
No grade 4 glycosuria events were reported (Table 5).
Integrated renal safety
The safety data from the HBe Ag-positive (437) and
HBeAg-negative (438) studies were pooled to enable the
safety profile of ADV 10 mg daily to be better evaluated in
a larger sample of patients when compared with placebo
and ADV 30 mg. By week 48, one patient (<1%) in the
placebo group and four patients (1%) in the ADV 10 mg
group had an unconfirmed increase in serum creatinine
of ≥0.5 mg/dL from baseline; none of these events were
confirmed on repeat testing, and by the next visit (on
study drug), all resolved to ≤0.3 mg/dL from baseline. By
week 96, Kaplan-Meier estimates showed that nine (6%)
patients in the all ADV 10 mg group had an unconfirmed
serum creatinine increase from baseline of ≥0.5 mg/dL.
None of these events were confirmed by two consecutive
laboratory assessments, and all resolved to ≤0.3 mg/dL
from baseline while the patients continued on ADV
10 mg. With respect to the 30 mg treatment arm in
study 437, the Kaplan-Meier estimate demonstrates that
21% of patients administered this dose experienced an
unconfirmed serum creatinine increase of ≥0.5 mg/dL
from baseline by week 48. In comparison, only two pa-
tients (1% Kaplan-Meier estimate) in the integrated
safety population for ADV 10 mg experienced an un-
confirmed serum creatinine ≥0.5 mg/dL increase from
baseline. The serum creatinine abnormalities in these two
patients were not confirmed as determined by two consec-
utive laboratory assessments. For serum phosphorus, the
Kaplan-Meier estimate showed that 16% of patients
in the ADV 30 mg group had an unconfirmed serum
phosphorus level of <2.0 mg/dL during 48 weeks of
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treatment. In the integrated safety population for ADV
10 mg, the Kaplan-Meier estimate for serum phosphorus
<2.0 mg/dL indicated that 3% of patients had this un-
confirmed event by week 48. No patient had a confirmed
serum phosphorus of <1.5 mg/dL in the integrated safety
analyses. By examining the Kaplan-Meier estimates for
time to onset of unconfirmed serum creatinine and serum
phosphorus abnormalities in the ADV 30 mg, it is clear
that these abnormalities were gradual in onset, and on
average, became apparent between approximately 20 to
30 weeks of therapy.
DISCUSSION
We have observed that ADV 10 mg was not nephro-
toxic with an incidence of renal events similar to that
observed with placebo group, 10% and 12%, respectively.
Moreover, ADV 30 mg was shown to be nephrotoxic,
with an incidence of 35% renal events. Previous studies
indicated that nephrotoxicity was the most important
dose-limiting toxicity of ADV therapy observed when
studied in patients with HIV-1 infection at doses of 60 and
120 mg daily. Toxicity of this drug appears to correlate
with an organic anion transporter (hOAT1)-mediated
cellular accumulation and transport of fluorescein-
methotrexate on multidrug resistance–associated
protein2 (Mrp2) [5–8]. Indeed, in vitro studies demon-
strated that over-expression of hOAT1 in Chinese
Hamster Ovary (CHO) cells exposed to adefovir and
cidofovir resulted in an increase in intracellular concen-
trations of both drugs [7]. ADV-related nephrotoxicity
manifests at doses ≥30 mg daily as a proximal renal
tubular dysfunction and elevated serum creatinine [9],
and is primary manifested by the onset of gradual
increases in serum creatinine and decrease in serum
phosphorus after 20 weeks of therapy. These changes
are usually mild to moderate in severity and can be
accompanied by changes in serum potassium, bicar-
bonate, uric acid, glycosuria, and proteinuria. The time
to onset of these changes appeared to be independent
of dosage. However, the incidence of these changes
appeared to be dose related. Analyses of these changes
in HIV-infected patients treated with ADV 120 mg daily
revealed that a confirmed increase in serum creatinine
of ≥0.5 mg/dL from baseline or a confirmed decrease in
serum phosphorus to <1.5 mg/dL were the most sensitive
and specific indicators of ADV-related nephrotoxicity.
Proximal renal tubular toxicity was documented in 22%
to 32% of patients treated with ADV dipivoxil 120 mg
for 48 weeks [9, 10]. In a randomized, double-blind,
placebo-controlled multicenter trial with 12 months’
follow-up, among the 253 HIV-patients assigned ADV
(120 mg once daily) and the 252 assigned placebo,
respectively, the cumulative incidence of patients with
proximal renal tubular dysfunction was 17.2% in the
ADV 120 mg group and 0.4% in the placebo group.
The median time to resolution of proximal renal tubular
dysfunction was 15 weeks among patients assigned ADV,
and 16% of patients did not resolve completely 41 weeks
after onset of nephrotoxicity. Data from a randomized
double-blind comparison of ADV 60 and 120 mg once
daily suggest that nephrotoxicity is less frequent with the
lower dosage regimen. Indeed, 27% and 50% of patients
treated with ADV 60 or 120 mg daily, respectively, had
a serum phosphorus level <2.0 mg/dL after 48 weeks
of treatment [11]. We have previously shown from an
uncontrolled study in patients with HIV-1 infection,
coinfection with HBV, that ADV is not nephrotoxic at
the dose of 10 mg daily [1, 12]. However, it must be out-
lined that renal abnormalities are frequently observed
in those patients. In our placebo control group from the
HBeAg-positive (437) and the HBeAg-negative (438)
studies, proteinuria, hematuria, and glycosuria (ranging
from grades 1 to 4) were reported in 28%, 49%, and 13%,
respectively, of the placebo-treated patients. Therefore,
a control group is necessary when assessing the renal
tolerance of any drug in those patients. In two recent
papers, Marcellin et al [2] and Hadziyannis et al [3] have
reported a complete analysis on the safety and efficacy of
48 weeks of ADV in patients with HBeAg-positive and
HBeAg-negative chronic hepatitis B. Treatment with
10 mg of ADV daily was well tolerated and significantly
improved histologic findings in the liver, reduced serum
HBV DNA levels, normalized ALT levels, and induced
HBeAg loss and seroconversion in a diverse multicenter
population. They also briefly analyzed the effect of
ADV on serum creatinine and serum phosphorus
level.
We have further analyzed the renal data in detail. From
this complete renal safety analysis, we confirm that ADV
nephrotoxicity is dose-related. At the dose of 30 mg daily,
serum creatinine grade 2 abnormalities were observed
in 13% compared with 27% and 50% in the adefovir
60 mg and 120 mg groups, respectively, in previous studies.
Furthermore, in these two studies, grade 1 serum creati-
nine increases were observed in 10%, 10%, and 0.5% for
ADV 30 mg, ADV 10 mg daily, and placebo-treated pa-
tients, respectively. Thus, at the dose of 30 mg daily, ADV
still induces renal abnormalities, although less than with
higher doses. Interestingly, in these two double-blind ran-
domized, placebo-controlled studies, ADV induced no
renal abnormalities at the dose of 10 mg compared with
placebo.
Hepatitis B infection has been linked with renal dis-
eases for decades. Hepatitis B virus (HBV)-associated
glomerulonephritides have been increasingly reported,
and the association between HBV and glomerulopathy is
striking, especially in children with a reported incidence
of nephrotic syndrome, nephritic syndrome, and both in
64%, 57%, and 35%, respectively [13].
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CONCLUSION
We confirm that the incidence of ADV nephrotoxicity
is dose-related, at all doses ≥30 mg daily, and that there is
no evidence of this toxicity at the currently and approved
dose of ADV 10 mg daily. Furthermore, low-grade re-
nal abnormalities are very frequently found in placebo
patients with chronic hepatitis B, reflecting the natural
history of chronic hepatitis B.
Reprint requests to Hassane Izzedine, Department of Nephrology,
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